STERIS plc

Informe acción NYSE:STE

Capitalización de mercado: US$20.0b

STERIS Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de STERIS de 10.2% y 6% por año respectivamente. Se prevé que el BPA crezca en un 10.7% al año. Se espera que la rentabilidad financiera sea de 13.8% en 3 años.

Información clave

10.2%

Tasa de crecimiento de los beneficios

10.72%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment16.9%
Tasa de crecimiento de los ingresos6.0%
Rentabilidad financiera futura13.79%
Cobertura de analistas

Good

Última actualización11 Sep 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Actualización de narrativa • Aug 09

STE: North Carolina Expansion And Dividend Growth Will Support Future Upside

Analysts have modestly raised their price target for STERIS to about $262 per share. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E.
Seeking Alpha • Jul 27

Steris: A Good Moment To Buy Shares In This Sterilization Leader

Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 24

STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside

Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.
Actualización de narrativa • Jun 04

STE: Share Repurchases And Earnings Outlook Will Support Future Upside

Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.
Actualización de narrativa • May 11

STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside

Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.
Actualización de narrativa • Apr 26

STE: Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).
Actualización de narrativa • Apr 11

STE: Completed Buyback And Stable Assumptions Will Support Future Upside

Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.
Actualización de narrativa • Mar 28

STE: Completed Buyback And Refined Assumptions Will Support Future Upside

Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.
Artículo de análisis • Mar 24

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...
Actualización de narrativa • Mar 11

STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.
Actualización de narrativa • Feb 25

STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside

Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.
Actualización de narrativa • Feb 10

STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View

Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.
Actualización de narrativa • Jan 27

STE: Share Repurchases And Stable Outlook Will Support A Fair View

Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).
Actualización de narrativa • Jan 10

STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook

Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.
Artículo de análisis • Jan 09

Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Artículo de análisis • Dec 26

Earnings Tell The Story For STERIS plc (NYSE:STE)

With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...
Actualización de narrativa • Dec 23

STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook

Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).
Actualización de narrativa • Dec 09

STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook

Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).
Actualización de narrativa • Nov 25

STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance

Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.
Actualización de narrativa • Nov 07

STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value

Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.
Artículo de análisis • Oct 27

Is STERIS (NYSE:STE) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Actualización de narrativa • Sep 05

Healthcare Demand And Facility Expansion Will Create Value

With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.
Seeking Alpha • Mar 22

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking Alpha
Seeking Alpha • Nov 18

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking Alpha

Previsiones de crecimiento de beneficios e ingresos

NYSE:STE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
3/31/20297,2071,173N/AN/A4
3/31/20286,7781,019N/A1,4419
3/31/20276,372889N/A1,3049
6/30/20266,0388059261,289N/A
3/31/20265,9367829721,341N/A
12/31/20255,8287099171,267N/A
9/30/20255,7036899611,301N/A
6/30/20255,5716489091,264N/A
3/31/20255,4606107781,148N/A
12/31/20245,3986177511,142N/A
9/30/20245,3265916801,101N/A
6/30/20245,235561594996N/A
3/31/20245,139551613973N/A
12/31/20234,6831,036594934N/A
9/30/20234,6011,012535849N/A
6/30/20234,563576494806N/A
3/31/20234,536557395757N/A
12/31/20224,784-28349713N/A
9/30/20224,777-8399752N/A
6/30/20224,773377472819N/A
3/31/20224,223285397685N/A
12/31/20214,248279412701N/A
9/30/20213,848250400662N/A
6/30/20213,407286424653N/A
3/31/20213,108397450690N/A
12/31/20203,057433476701N/A
9/30/20203,022424400627N/A
6/30/20203,003413384615N/A
3/31/20203,031408N/A591N/A
12/31/20192,976393N/A570N/A
9/30/20192,898336N/A573N/A
6/30/20192,840319N/A548N/A
3/31/20192,782304N/A540N/A
12/31/20182,730269N/A490N/A
9/30/20182,696316N/A467N/A
6/30/20182,651303N/A478N/A
3/31/20182,620291N/A458N/A
12/31/20172,585243N/A463N/A
9/30/20172,570144N/A453N/A
6/30/20172,582120N/A424N/A
3/31/20172,613110N/A424N/A
12/31/20162,616142N/A439N/A
9/30/20162,588167N/A364N/A
6/30/20162,431135N/A294N/A
3/31/20162,233111N/A255N/A
12/31/20152,04294N/A185N/A
9/30/20151,897113N/A221N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10.2% al año) de STE es superior a la tasa de ahorro (3.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (10.2% al año) de STE crezcan menos que el mercado US (17.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de STE crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (6% al año) de STE crezcan más despacio que el mercado de US (13.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6% al año) de STE crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de STE sea baja dentro de 3 años (13.8%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/09/21 03:05
Precio de las acciones al final del día2026/09/21 00:00
Beneficios2026/06/30
Ingresos anuales2026/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

STERIS plc está cubierta por 17 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Michael PolarkBaird
Erin Wilson WrightBofA Global Research
David TurkalyCitizens JMP Securities, LLC